Lead Program (Autoimmunity)

About Immetas Therapeutics

Immetas Therapeutics is a private, preclinical-stage biotech targeting the nexus of aging and chronic inflammation. The company's scientific premise is that chronic low-grade inflammation is a fundamental driver of aging and age-related diseases, including cancer and autoimmune disorders. Leveraging emerging research from labs like the Sinclair Lab, Immetas aims to develop therapeutics that modulate innate and adaptive immune responses. Its approach is to translate abundant clinical evidence on immune-targeting drugs into novel treatments for a broad range of age-associated conditions.

Therapeutic Areas

Other Autoimmune/Inflammatory Diseases Drugs